In short
Most medical device manufacturers sell indirectly — through distributors, GPOs, and IDNs — which means they often can't see who their real end customer is, what that customer needs, or why a purchase decision was made. Industry research shows this gap runs deep: customer data arrives late and fragmented, and most manufacturers can't see past their first tier of suppliers either. This isn't only a channel-management problem. AI systems recommend a company based on specific, structured facts about who its product serves — and a company that can't see its own customers clearly usually can't describe them clearly either, to a person or to an algorithm. Fixing Commercial Readiness and fixing AI/GEO Visibility turn out to depend on the same underlying work: consolidating a fragmented picture of who your customers actually are.
Ask a medical device company how its product moves from the factory to the operating room, and most can answer confidently: through distributors, group purchasing organizations, integrated delivery networks, hospital supply chains. Ask the same company exactly who is buying it, why, and how that decision got made — and the confidence usually drops.
That's not a knowledge problem inside any one department. It's structural.
Most Device Revenue Never Touches the Manufacturer Directly
Industry analysis of medical device commercial operations describes the pattern plainly: sales can be direct, or indirect through distributors, and indirect sales make it genuinely difficult to have visibility of the end customer. In many cases, customer data arrives from external sources on a lag rather than in real time. Layer on top of that the broader shift in U.S. healthcare — hospital consolidation, the growth of GPOs, integrated delivery networks, accountable care organizations, and Value Analysis Committees — and the relationship between a manufacturer's commercial team and the people actually deciding on its product gets several steps longer than it used to be. (MedTech Intelligence)
The same source identifies specific structural reasons this is hard to fix. A device company typically needs a customer view at the enterprise, sales area, transaction, company code, and relationship level all at once. Most transactions happen at an account level — a hospital or IDN — with purchasing centralized well above the individual clinician. Sales moving through distributors adds a layer the manufacturer doesn't control. And the same customer account can be identified differently across systems, using different tax IDs, global location numbers, or internal codes, so what looks like several different customers may actually be one.
The Same Blindness Runs Upstream, Not Just Downstream
It isn't only the customer-facing side of the business that loses resolution the further it gets from the manufacturer. The supply side shows the identical pattern in reverse.
15%
of chief procurement officers report having supply chain visibility beyond their tier-1 suppliers, per 2022 research.
Deloitte, cited via Millstone MedicalTier 1
is typically as far as most medtech manufacturers can see — even for those immediate suppliers, few companies track a full set of risk factors.
McKinsey, cited via Millstone MedicalPut the two findings together and a pattern emerges that has nothing to do with any single company's competence: the further a fact sits from the manufacturer — toward either the supplier or the customer — the less reliably that manufacturer can see it. (Millstone Medical)
Why This Is Also an AI Visibility Problem
Here's the connection that's easy to miss: the knowledge gap that weakens channel strategy is the same knowledge gap that keeps a company illegible to AI.
An AI system recommending a medical device to a physician, a distributor, or a hospital procurement team isn't working from vague impressions. It's matching specific facts — this specialty, this procedure, this site of care, this stakeholder's actual question — against whatever structured information exists about a company. If a manufacturer's own internal picture of its customers is fragmented across distributor CRMs, GPO contract terms, and disconnected account records, that fragmentation doesn't stay contained inside the company. It shows up externally too — in vague product pages, generic positioning, and content that never quite says who the product is actually for, because nobody inside the company has a single, reliable answer to that question either.
This is why the decision chain matters so much in medical device commercialization: the surgeon, the OR staff, the Value Analysis Committee, supply chain, the hospital or ASC, the distributor, and the GPO or IDN each ask a different question before a product gets adopted. A company that can't say with confidence which of these stakeholders is actually driving its revenue in a given account has no reliable way to write content — or supply facts to AI — specific enough to answer any of their questions convincingly.
What Fixing Channel Visibility Actually Requires
| Data element | Why it fragments |
|---|---|
| Customer identifiers | The same hospital or IDN may appear under different tax IDs, global location numbers, or internal codes across systems |
| Account-level views | Purchasing is centralized above the individual clinician, but product data is often tracked at the SKU level instead |
| Channel layer | Distributors and GPOs sit between the manufacturer and the point of use, each holding data the manufacturer doesn't see directly |
| Timing | Customer and usage data frequently arrives from external sources on a lag rather than in real time |
None of this gets solved by writing more marketing content. It gets solved by consolidating these fragments into one accurate, structured picture of who the actual customer is — which then becomes the same source of truth that both a sales team and an AI system can draw from.
The channel visibility loop
Fragmented Customer Data→No Single Source of Truth→Generic Positioning→Weak Channel Strategy→Weak AI/GEO Visibility
Break the loop at the source — a structured customer and decision-chain map — and both sides improve together.
Sources referenced in this article
MedTech Intelligence, "Addressing Data Challenges in MedTech" — medtechintelligence.com
Millstone Medical, "Five Reasons Why Supply Chain Visibility Matters in Medical Device Manufacturing," citing McKinsey (2020) and Deloitte (2022) research — millstonemedical.com
Frequently Asked Questions
What is the channel visibility problem in medical device sales?
It refers to a manufacturer's inability to see clearly who is actually buying, using, and deciding on its products once sales move through distributors, GPOs, or IDNs rather than direct channels. Customer data often arrives from external sources on a lagging basis, and the same account can be fragmented across different identifiers and product hierarchies, making it hard to build a single, reliable view of the end customer.
Why is supply chain visibility so limited beyond tier-1 suppliers?
Most manufacturers only have direct data-sharing relationships with their immediate suppliers. Beyond that first tier, visibility depends on those suppliers voluntarily sharing information about their own suppliers, which most supply chains aren't structured to do. Industry research has found that only a small minority of procurement leaders report having visibility beyond their tier-1 suppliers.
How does distributor data fragmentation affect a company's ability to be found by AI?
AI systems recommend a company based on structured, specific facts about who its product serves and why. If a company's own customer and usage data is fragmented across distributor CRMs, GPO contracts, and disconnected internal systems, that same fragmentation shows up in its public content — it becomes generic because the underlying facts were never consolidated into one accurate source. Fixing internal channel visibility and improving AI visibility draw on the same underlying work.
What data elements should a medical device company unify to fix this?
Common priorities include consistent customer identifiers (such as tax ID or global location number) across systems, account-level data that spans multiple product hierarchies rather than isolated SKUs, and a shared definition of who counts as the end customer versus the distributor or GPO negotiating the contract. Without this, the same customer can appear as several disconnected records across different systems.
Why do GPOs, IDNs, and VACs make this harder?
Group purchasing organizations, integrated delivery networks, and Value Analysis Committees centralize purchasing decisions above the level of the individual clinician or hospital department. This adds layers between the manufacturer and the actual point of use, and each layer can hold data the manufacturer never sees directly, further separating clinical demand from the commercial relationship.
How does Commercial Readiness relate to AI/GEO Visibility?
Commercial Readiness asks whether a company knows who uses, influences, approves, and pays for its product. AI/GEO Visibility asks whether AI systems and buyers can find, understand, and verify that same information online. Both depend on the same underlying asset — a structured, accurate picture of the company's actual customers and decision chain — so a gap in one area is usually a symptom of a gap in the other.
Next step
Commercial Readiness and AI Visibility, diagnosed together
The Alzaro MedTech Market Access OS treats Commercial Readiness and AI/GEO Visibility as connected, not separate — because in practice, a gap in one is almost always a symptom of the other. Part of the diagnostic maps your actual decision chain (who uses, influences, approves, purchases, and distributes your product) against what your current content and channel data can actually prove.